<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Nephrol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Nephrol</journal-id><journal-title-group><journal-title>BMC Nephrology</journal-title></journal-title-group><issn pub-type="epub">1471-2369</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23731573</article-id><article-id pub-id-type="pmc">3682900</article-id><article-id pub-id-type="publisher-id">1471-2369-14-119</article-id><article-id pub-id-type="doi">10.1186/1471-2369-14-119</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>N-acetylcysteine does not prevent contrast nephropathy in patients with renal impairment undergoing emergency CT: a randomized study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Poletti</surname><given-names>Pierre-Alexandre</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Pierre-Alexandre.Poletti@hcuge.ch</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Platon</surname><given-names>Alexandra</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Alexandra.Platon@hcuge.ch</email></contrib><contrib contrib-type="author" id="A3"><name><surname>De Seigneux</surname><given-names>Sophie</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Sophie.deSeigneux@hcuge.ch</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Dupuis-Lozeron</surname><given-names>Elise</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>Elise.DupuisLozeron@hcuge.ch</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Sarasin</surname><given-names>François</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>Francois.Sarasin@hcuge.ch</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Becker</surname><given-names>Christoph D</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Christoph.Becker@hcuge.ch</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Perneger</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>Thomas.Perneger@hcuge.ch</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Saudan</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Patrick.Saudan@hcuge.ch</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Martin</surname><given-names>Pierre-Yves</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Pierre-Yves.Martin@hcuge.ch</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Radiology, University Hospital of Geneva, Geneva, Switzerland</aff><aff id="I2"><label>2</label>Service of Nephrology, Department of Internal Medicine specialties, University Hospital of Geneva, Geneva, Switzerland</aff><aff id="I3"><label>3</label>Division of Clinical Epidemiology, University Hospital of Geneva, Geneva, Switzerland</aff><aff id="I4"><label>4</label>Service of Emergency Medicine, University Hospital of Geneva, Geneva, Switzerland</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>3</day><month>6</month><year>2013</year></pub-date><volume>14</volume><fpage>119</fpage><lpage>119</lpage><history><date date-type="received"><day>6</day><month>11</month><year>2012</year></date><date date-type="accepted"><day>9</day><month>5</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2013 Poletti et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Poletti et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2369/14/119"></self-uri><abstract><sec><title><offsets xml_i="4670" xml_f="4680" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4691" xml_f="5014" txt_i="22" txt_f="345">Patients admitted to the emergency room with renal impairment and undergoing a contrast computed tomography (CT) are at high risk of developing contrast nephropathy as emergency precludes sufficient hydration prior to contrast use. The value of an ultra-high dose of intravenous N-acetylcysteine in this setting is unknown.</offsets></p></sec><sec><title><offsets xml_i="5036" xml_f="5043" txt_i="347" txt_f="354">Methods</offsets></title><p><offsets xml_i="5054" xml_f="5198" txt_i="355" txt_f="499">From 2008 to 2010, we randomized 120 consecutive patients admitted to the emergency room with an estimated clearance lower than 60 ml/min/1.73 m</offsets><sup><offsets xml_i="5203" xml_f="5204" txt_i="499" txt_f="500">2</offsets></sup><offsets xml_i="5210" xml_f="5245" txt_i="500" txt_f="535"> by MDRD (mean GFR 42 ml/min/1.73 m</offsets><sup><offsets xml_i="5250" xml_f="5251" txt_i="535" txt_f="536">2</offsets></sup><offsets xml_i="5257" xml_f="5607" txt_i="536" txt_f="886">) to either placebo or 6000 mg N-acetylcysteine iv one hour before contrast CT in addition to iv saline. Serum cystatin C and creatinine were measured one hour prior to and at day 2, 4 and 10 after contrast injection. Nephrotoxicity was defined either as 25% or 44 μmol/l increase in serum creatinine or cystatin C levels compared to baseline values.</offsets></p></sec><sec><title><offsets xml_i="5629" xml_f="5636" txt_i="888" txt_f="895">Results</offsets></title><p><offsets xml_i="5647" xml_f="5958" txt_i="896" txt_f="1207">Contrast nephrotoxicity occurred in 22% of patients who received placebo (13/58) and 27% of patients who received N-acetylcysteine (14/52, p = 0.66). Ultra-high dose intravenous N-acetylcysteine did not alter creatinine or cystatin C levels. No secondary effects were noted within the 2 groups during follow-up.</offsets></p></sec><sec><title><offsets xml_i="5980" xml_f="5991" txt_i="1209" txt_f="1220">Conclusions</offsets></title><p><offsets xml_i="6002" xml_f="6164" txt_i="1221" txt_f="1383">An ultra-high dose of intravenous N-acetylcysteine is ineffective at preventing nephrotoxicity in patients with renal impairment undergoing emergency contrast CT.</offsets></p></sec><sec><title><offsets xml_i="6186" xml_f="6204" txt_i="1385" txt_f="1403">Trial registration</offsets></title><p><offsets xml_i="6215" xml_f="6259" txt_i="1404" txt_f="1448">The study was registered as Clinical trial (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT01467154?term=2008DR4057&amp;rank=1"><offsets xml_i="6380" xml_f="6391" txt_i="1448" txt_f="1459">NCT01467154</offsets></ext-link><offsets xml_i="6402" xml_f="6404" txt_i="1459" txt_f="1461">).</offsets></p></sec></abstract><kwd-group><kwd>Computerized Tomography</kwd><kwd>Contrast media</kwd><kwd>Emergency medicine</kwd><kwd>N-acetylcysteine</kwd><kwd>Nephrotoxicity</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="6629" xml_f="6639" txt_i="1470" txt_f="1480">Background</offsets></title><p><offsets xml_i="6650" xml_f="6782" txt_i="1481" txt_f="1613">Prevention of acute kidney injury (AKI) post contrast injection remains mandatory given its association to morbidity and mortality [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="6813" xml_f="6814" txt_i="1613" txt_f="1614">1</offsets></xref><offsets xml_i="6821" xml_f="6823" txt_i="1614" txt_f="1616">].</offsets></p><p><offsets xml_i="6830" xml_f="7019" txt_i="1617" txt_f="1806">Contrast nephropathy (CN) is classically defined as an increase in 25% or more, or as an absolute increase of 44 μmol/l of creatinine levels within three days following contrast injection [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="7050" xml_f="7051" txt_i="1806" txt_f="1807">2</offsets></xref><offsets xml_i="7058" xml_f="7258" txt_i="1807" txt_f="2007">]. Recently, AKIN (acute kidney injury network) and RIFLE (risk, injury, failure loss and end-stage kidney disease) criteria have emerged to standardize the diagnosis of AKI in hospitalized patients [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="7289" xml_f="7290" txt_i="2007" txt_f="2008">3</offsets></xref><offsets xml_i="7297" xml_f="7407" txt_i="2008" txt_f="2118">]. These criteria are important as they correlate to mortality in critically and non critically ill patients [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="7438" xml_f="7439" txt_i="2118" txt_f="2119">4</offsets></xref><offsets xml_i="7446" xml_f="7447" txt_i="2119" txt_f="2120">-</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="7478" xml_f="7479" txt_i="2120" txt_f="2121">6</offsets></xref><offsets xml_i="7486" xml_f="7597" txt_i="2121" txt_f="2232">]. AKIN criteria have rarely been used for CN but appear to also predict mortality in critically ill patients [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="7628" xml_f="7629" txt_i="2232" txt_f="2233">7</offsets></xref><offsets xml_i="7636" xml_f="7757" txt_i="2233" txt_f="2354">]. Finally, other markers such as cystatin C or NGAL may be more sensitive to identify CN and also to predict mortality [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="7788" xml_f="7789" txt_i="2354" txt_f="2355">8</offsets></xref><offsets xml_i="7796" xml_f="7867" txt_i="2355" txt_f="2426">] although a definition of CN using these markers is currently lacking.</offsets></p><p><offsets xml_i="7874" xml_f="8091" txt_i="2427" txt_f="2644">In patients undergoing elective radiological or cardiologic procedures, CN can be prevented by hydration, withdrawal of diuretics and/or nephrotoxic drugs. Its prevalence has therefore declined over the recent years [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="8122" xml_f="8123" txt_i="2644" txt_f="2645">9</offsets></xref><offsets xml_i="8130" xml_f="8352" txt_i="2645" txt_f="2867">]. Occurrence of CN is however consistently higher in diabetics, congestive heart failure patients, volume depleted patients, critically ill patients and especially in patients suffering from chronic kidney disease (CKD) [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="8383" xml_f="8384" txt_i="2867" txt_f="2868">7</offsets></xref><offsets xml_i="8391" xml_f="8392" txt_i="2868" txt_f="2869">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="8424" xml_f="8426" txt_i="2869" txt_f="2871">10</offsets></xref><offsets xml_i="8433" xml_f="8434" txt_i="2871" txt_f="2872">-</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="8466" xml_f="8468" txt_i="2872" txt_f="2874">12</offsets></xref><offsets xml_i="8475" xml_f="8823" txt_i="2874" txt_f="3219">]. Emergency CT with contrast injection in patients with renal impairment (eGFR &lt; 60 ml/min) remains an important cause of contrast nephropathy given the lack of sufficient time for hydration and the lack of renal functional reserve. Finding an efficient prevention for contrast nephropathy in this specific population would be highly desirable.</offsets></p><p><offsets xml_i="8830" xml_f="8895" txt_i="3220" txt_f="3285">N-acetylcysteine (NAC) may protect against contrast nephropathy [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="8927" xml_f="8929" txt_i="3285" txt_f="3287">13</offsets></xref><offsets xml_i="8936" xml_f="8995" txt_i="3287" txt_f="3346">]. While hydration is clearly beneficial in preventing CN [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="9027" xml_f="9029" txt_i="3346" txt_f="3348">14</offsets></xref><offsets xml_i="9036" xml_f="9177" txt_i="3348" txt_f="3489">], the role of NAC administration is still uncertain and results of randomized control trials gave conflicting results regarding its effect [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="9209" xml_f="9211" txt_i="3489" txt_f="3491">15</offsets></xref><offsets xml_i="9218" xml_f="9307" txt_i="3491" txt_f="3580">]. In addition, NAC does not seem to prevent AKI in patients with normal renal function [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="9339" xml_f="9341" txt_i="3580" txt_f="3582">16</offsets></xref><offsets xml_i="9348" xml_f="9699" txt_i="3582" txt_f="3933">]. Intravenous NAC may be the form of choice in emergency procedures given its rapid availability and its ease of administration in patients whose consciousness is altered or who cannot eat. However, when using the iv route in emergency, higher doses of NAC (6000 mg) may be necessary to obtain a preventive effect as tested by Marenzi and collegues [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="9731" xml_f="9733" txt_i="3933" txt_f="3935">17</offsets></xref><offsets xml_i="9740" xml_f="9914" txt_i="3935" txt_f="4109">]. Furthermore, the Rappid study also demonstrated that high dose iv NAC was efficient in prevention of CN, with doses derived from the one used in paracetamol intoxication [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="9946" xml_f="9948" txt_i="4109" txt_f="4111">18</offsets></xref><offsets xml_i="9955" xml_f="10080" txt_i="4111" txt_f="4236">]. Indeed, NAC administered by the intravenous route may be less effective in generating gluthatione than when given orally [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="10112" xml_f="10114" txt_i="4236" txt_f="4238">19</offsets></xref><offsets xml_i="10121" xml_f="10316" txt_i="4238" txt_f="4433">]. Finally, in a previous study performed in patients with elevated creatinine levels undergoing emergency CT-Scan, 1800 mg of NAC administered iv failed to prevent contrast induced nephropathy [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="10348" xml_f="10350" txt_i="4433" txt_f="4435">20</offsets></xref><offsets xml_i="10357" xml_f="10359" txt_i="4435" txt_f="4437">].</offsets></p><p><offsets xml_i="10366" xml_f="10640" txt_i="4438" txt_f="4712">The aim of the present study was therefore to determine whether 6000 mg (ultra high dose) intravenous NAC, to account for a dose dependent effect, was efficient in preventing CN after emergency contrast CT-scan in patients admitted to the ER with elevated creatinine levels.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="10681" xml_f="10688" txt_i="4714" txt_f="4721">Methods</offsets></title><p><offsets xml_i="10699" xml_f="10836" txt_i="4722" txt_f="4859">From 2008 to 2010, 124 consecutive patients were eligible in the emergency room on account of an estimated creatinine clearance by MDRD [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="10868" xml_f="10870" txt_i="4859" txt_f="4861">21</offsets></xref><offsets xml_i="10877" xml_f="10908" txt_i="4861" txt_f="4892">] of less than 60 ml/min/1.73 m</offsets><sup><offsets xml_i="10913" xml_f="10914" txt_i="4892" txt_f="4893">2</offsets></sup><offsets xml_i="10920" xml_f="11440" txt_i="4893" txt_f="5413"> and a request for an urgent contrast CT. Exclusion criteria were asthma, pregnancy, obstructive nephropathy and patients’s refusal. Written consent was obtained from every patient and from a physician independent from the study. 4 patients refused to participate to the study. 120 patients were randomized to placebo or high dose iv NAC. The study was approved by the ethical committee of the University Hospital of Geneva (IRB 07–121) as well as by the Swiss Agency for Therapeutic Products (Swissmedic, N°2008DR4057).</offsets></p><p><offsets xml_i="11447" xml_f="11581" txt_i="5414" txt_f="5548">Iohexol (Accupaque®, GE Healthcare, Opfikon) was the contrast medium used in this study at a dose of 1.5 ml/kg to a maximum of 150 ml.</offsets></p><sec><title><offsets xml_i="11597" xml_f="11611" txt_i="5549" txt_f="5563">Study protocol</offsets></title><p><offsets xml_i="11622" xml_f="12140" txt_i="5564" txt_f="6082">Patients were randomized to either placebo (0.45% saline) or high dose (6000 mg) iv NAC (Fluimicil®, Zambon, Cadempino, Switzerland) diluted in 100 ml 0.45% saline to be administered during the 60 minutes before the CT-Scan. The randomization list was generated by computer, and NAC or placebo vials were prepared and numbered accordingly by the pharmacy. Investigators, patients and patient’s primary physician were blinded to treatment group. No patients in the control group received NAC outside the study protocol.</offsets></p><p><offsets xml_i="12147" xml_f="12662" txt_i="6083" txt_f="6598">Randomized patients were then assigned to hydration of 250 ml of 0.45% NaCl before the CT-Scan and blindly allocated to either high dose NAC versus placebo. After the CT-Scan, all patients received 1000 ml NaCl 0.45%. Creatinine and cystatin C serum levels were collected one hour before CT-Scan and at day 2, 4 and 10. The T0 value for creatinine and cystatin C was the value measured before the CT-Scan. Serum Creatinine and Cystatin C were measured by the Jaffe method, and by a nephelometric assay respectively.</offsets></p></sec><sec><title><offsets xml_i="12684" xml_f="12700" txt_i="6600" txt_f="6616">Outcome measures</offsets></title><p><offsets xml_i="12711" xml_f="13500" txt_i="6617" txt_f="7406">The primary endpoint of the study was the occurrence of contrast nephropathy at day 2, 4 or 10, which was defined as an increase of at least 25% or 44 μmol/l in serum creatinine level or 25% increase in cystatin C levels at day 2, 4 or 10 compared to day 0. We also assessed the proportion of patients with contrast nephropathy regarding the biomarkers used and according to AKIN criteria. The AKIN criteria defined a stage 1 AKI as an increase in creatinine between 150% and 199% from baseline or an absolute increase of at least 26.2 μmol/l, a stage 2 AKI as an increase between 200% and 299% from baseline and a stage 3 AKI as an increase of at least 300% from baseline or a creatinine concentration higher than 354 umol/l with an acute rise of at least 44 μmol/l or initiation of RRT [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="13532" xml_f="13534" txt_i="7406" txt_f="7408">22</offsets></xref><offsets xml_i="13541" xml_f="13543" txt_i="7408" txt_f="7410">].</offsets></p><p><offsets xml_i="13550" xml_f="13751" txt_i="7411" txt_f="7612">Secondary endpoints were the mean increases in creatinine and cystatin C concentrations on days 2, 4 and 10 along with the maximum increase during the time periods from day 2 to day 10 (peak increase).</offsets></p></sec><sec><title><offsets xml_i="13773" xml_f="13793" txt_i="7614" txt_f="7634">Statistical analysis</offsets></title><p><offsets xml_i="13804" xml_f="13831" txt_i="7635" txt_f="7662">Based on a previous study [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="13863" xml_f="13865" txt_i="7662" txt_f="7664">17</offsets></xref><offsets xml_i="13872" xml_f="14126" txt_i="7664" txt_f="7918">], the proportion of patient with nephropathy was estimated to be 15% in NAC group and 33% in control group. To achieve a power of 90% and a two-tailed risk alpha, the minimal required sample size has been estimated to 106 patients (Fisher’s exact test).</offsets></p><p><offsets xml_i="14133" xml_f="14846" txt_i="7919" txt_f="8632">All analyses were performed on an intention-to-treat basis. Data were described as mean +/− SD. Proportions of patients in the control and the NAC groups were compared using Fisher’s exact test. Mean increases in creatinine and cystatin C concentrations were compared between the two groups by use of Mann–Whitney test. Sensitivity analyses were performed to assess the possible effects of loss to follow-up or death on the primary analysis. Pearson’s correlation coefficient was computed between creatinine and cystatin C measures for each day. The significance level was fixed to 0.05 (two-tailed). All statistical calculations were performed using R for Windows (Version 2.11.1, R Development Core Team, 2010).</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="14893" xml_f="14900" txt_i="8635" txt_f="8642">Results</offsets></title><sec><title><offsets xml_i="14920" xml_f="14935" txt_i="8643" txt_f="8658">Data collection</offsets></title><p><offsets xml_i="14946" xml_f="14985" txt_i="8659" txt_f="8698">Of the 120 randomized patients (Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="15015" xml_f="15016" txt_i="8698" txt_f="8699">1</offsets></xref><offsets xml_i="15023" xml_f="15150" txt_i="8699" txt_f="8826">), 6 were excluded of the study because they did not undergo contrast CT (n = 4) or presented with a renal obstruction (n = 2).</offsets></p><fig id="F1" position="float"><label><offsets xml_i="15191" xml_f="15199" txt_i="8827" txt_f="8835">Figure 1</offsets></label><caption><p><offsets xml_i="15219" xml_f="15263" txt_i="8835" txt_f="8879">Flow-chart summarizing the study population.</offsets></p></caption><graphic xlink:href="1471-2369-14-119-1"></graphic></fig><p><offsets xml_i="15337" xml_f="15636" txt_i="8880" txt_f="9179">Follow up did not allow qualification of contrast nephropathy in 4 patients (one in the placebo group, three in NAC group) because they died at day 0 (n = 2) or where lost immediately to follow up (n = 2). These patients were excluded from the main analysis but included in the sensitivity analysis.</offsets></p><p><offsets xml_i="15643" xml_f="15916" txt_i="9180" txt_f="9453">In the remaining 110 patients, 8 patients did not have creatinine and cystatin C measured at day 4 either because they died before (n = 4), or because follow up was interrupted (n = 2) and two for technical reasons. Cystatin C at day 4 was not obtained in 7 other patients.</offsets></p><p><offsets xml_i="15923" xml_f="16177" txt_i="9454" txt_f="9708">Eleven patients did not have creatinine and cystatin C measurement at day 10, either because they died before (n = 6), or they could not be reached (n = 4) or for technical reasons (n = 1). Seven other patients did not have cystatin C measured at day 10.</offsets></p></sec><sec><title><offsets xml_i="16199" xml_f="16231" txt_i="9710" txt_f="9742">Baseline patient characteristics</offsets></title><p><offsets xml_i="16242" xml_f="16461" txt_i="9743" txt_f="9962">At randomization, patients’ demographic and clinical characteristics were similar between the two treatment groups. Treatment medications were also similar between the groups. All baseline parameters are shown in Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="16493" xml_f="16494" txt_i="9962" txt_f="9963">1</offsets></xref><offsets xml_i="16501" xml_f="16560" txt_i="9963" txt_f="10022">. Mean estimated GFR according to MDRD was 42 ml/min/1.73 m</offsets><sup><offsets xml_i="16565" xml_f="16566" txt_i="10022" txt_f="10023">2</offsets></sup><offsets xml_i="16572" xml_f="16643" txt_i="10023" txt_f="10091">. Sixty-nine (61%) of the 114 patients had a eGFR &lt; 45 ml/min/1.73 m</offsets><sup><offsets xml_i="16648" xml_f="16649" txt_i="10091" txt_f="10092">2</offsets></sup><offsets xml_i="16655" xml_f="16695" txt_i="10092" txt_f="10129">; 10 (9%) had eGFR &lt; 30 ml/min/1.73 m</offsets><sup><offsets xml_i="16700" xml_f="16701" txt_i="10129" txt_f="10130">2</offsets></sup><offsets xml_i="16707" xml_f="16721" txt_i="10130" txt_f="10144"> on admission.</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="16769" xml_f="16776" txt_i="10145" txt_f="10152">Table 1</offsets></label><caption><p><offsets xml_i="16796" xml_f="16855" txt_i="10152" txt_f="10211">Patients characteristic with regard to the inclusion groups</offsets></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="left"></col><col align="left"></col></colgroup><thead valign="top"><tr><th align="left"><bold><offsets xml_i="17057" xml_f="17072" txt_i="10212" txt_f="10227">Characteristics</offsets></bold></th><th align="left"><bold><offsets xml_i="17107" xml_f="17117" txt_i="10227" txt_f="10237">Placebo (n</offsets></bold><offsets xml_i="17124" xml_f="17127" txt_i="10237" txt_f="10240"> = </offsets><bold><offsets xml_i="17133" xml_f="17136" txt_i="10240" txt_f="10243">59)</offsets></bold></th><th align="left"><bold><offsets xml_i="17171" xml_f="17177" txt_i="10243" txt_f="10249">NAC (n</offsets></bold><offsets xml_i="17184" xml_f="17187" txt_i="10249" txt_f="10252"> = </offsets><bold><offsets xml_i="17193" xml_f="17196" txt_i="10252" txt_f="10255">55)</offsets></bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><offsets xml_i="17278" xml_f="17289" txt_i="10255" txt_f="10266">Age (years)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="17336" xml_f="17346" txt_i="10267" txt_f="10277">78.2 ±11.8</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="17393" xml_f="17404" txt_i="10278" txt_f="10289">78.1 ± 12.0</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="17460" xml_f="17469" txt_i="10290" txt_f="10299">Sex (M/F)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="17516" xml_f="17521" txt_i="10300" txt_f="10305">29/30</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="17568" xml_f="17573" txt_i="10306" txt_f="10311">28/27</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="17629" xml_f="17640" txt_i="10312" txt_f="10323">BMI (kg/m2)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="17687" xml_f="17697" txt_i="10324" txt_f="10334">24.4 ± 4.6</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="17744" xml_f="17754" txt_i="10335" txt_f="10345">25.0 ± 4.8</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="17810" xml_f="17818" txt_i="10346" txt_f="10354">Diabetes</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="17865" xml_f="17873" txt_i="10355" txt_f="10363">11 (19%)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="17920" xml_f="17928" txt_i="10364" txt_f="10372">15 (27%)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="17984" xml_f="18005" txt_i="10373" txt_f="10394">Blood pressure (mmHg)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="18052" xml_f="18053" txt_i="10395" txt_f="10396"> </offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="18100" xml_f="18101" txt_i="10397" txt_f="10398"> </offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="18157" xml_f="18169" txt_i="10399" txt_f="10411">   Diastolic</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="18216" xml_f="18227" txt_i="10412" txt_f="10423">69.1 ± 11.7</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="18274" xml_f="18285" txt_i="10424" txt_f="10435">67.0 ± 17.2</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="18341" xml_f="18352" txt_i="10436" txt_f="10447">   Systolic</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="18399" xml_f="18411" txt_i="10448" txt_f="10460">129.5 ± 20.8</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="18458" xml_f="18470" txt_i="10461" txt_f="10473">132.9 ± 22.5</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="18526" xml_f="18546" txt_i="10474" txt_f="10494">Contrast medium (mL)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="18593" xml_f="18604" txt_i="10495" txt_f="10506">117.7 ± 3.2</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="18651" xml_f="18662" txt_i="10507" txt_f="10518">117.4 ± 1.8</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="18718" xml_f="18737" txt_i="10519" txt_f="10538">Creatinine (μmol/L)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="18784" xml_f="18796" txt_i="10539" txt_f="10551">133.5 ± 34.8</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="18843" xml_f="18855" txt_i="10552" txt_f="10564">132.4 ± 34.8</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="18911" xml_f="18928" txt_i="10565" txt_f="10582">Cystatin C (mg/L)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="18975" xml_f="18984" txt_i="10583" txt_f="10592">1.9 ± 0.5</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="19031" xml_f="19040" txt_i="10593" txt_f="10602">1.9 ± 0.6</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="19096" xml_f="19121" txt_i="10603" txt_f="10628">eGFR (MDRD) (ml/min/1.73)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="19168" xml_f="19178" txt_i="10629" txt_f="10639">41.7 ± 1.2</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="19225" xml_f="19235" txt_i="10640" txt_f="10650">42.7 ± 1.2</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="19291" xml_f="19302" txt_i="10651" txt_f="10662">Antibiotics</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="19349" xml_f="19357" txt_i="10663" txt_f="10671">16 (27%)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="19404" xml_f="19412" txt_i="10672" txt_f="10680">16 (29%)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="19468" xml_f="19525" txt_i="10681" txt_f="10738">Angiotensin-converting enzyme inhibitor (ACE-1 inhibitor)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="19572" xml_f="19580" txt_i="10739" txt_f="10747">28 (48%)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="19627" xml_f="19635" txt_i="10748" txt_f="10756">25 (45%)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="19691" xml_f="19736" txt_i="10757" txt_f="10802">Non-steroidal antiinflammatory drugs (NSAIDS)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="19783" xml_f="19789" txt_i="10803" txt_f="10809">1 (2%)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="19836" xml_f="19842" txt_i="10810" txt_f="10816">5 (9%)</offsets><hr></hr></td></tr><tr><td align="left"><offsets xml_i="19882" xml_f="19891" txt_i="10817" txt_f="10826">Diuretics</offsets></td><td align="left"><offsets xml_i="19913" xml_f="19921" txt_i="10827" txt_f="10835">27 (46%)</offsets></td><td align="left"><offsets xml_i="19943" xml_f="19951" txt_i="10836" txt_f="10844">25 (45%)</offsets></td></tr></tbody></table></table-wrap></sec><sec><title><offsets xml_i="20008" xml_f="20015" txt_i="10846" txt_f="10853">Outcome</offsets></title><p><offsets xml_i="20026" xml_f="20324" txt_i="10854" txt_f="11152">Of the 114 randomized patients, data were available for 110 patients. Out of these 110 patients, 52 received NAC and 58 the placebo. The number of patients who developed contrast nephropathy ranged between 16% (18/110) and 24.5% (27/110), depending on the definition of contrast nephropathy (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="20356" xml_f="20357" txt_i="11152" txt_f="11153">2</offsets></xref><offsets xml_i="20364" xml_f="20486" txt_i="11153" txt_f="11275">). There was no difference between the placebo and the NAC groups, irrespective of the definition of contrast nephropathy.</offsets></p><table-wrap position="float" id="T2"><label><offsets xml_i="20534" xml_f="20541" txt_i="11276" txt_f="11283">Table 2</offsets></label><caption><p><offsets xml_i="20561" xml_f="20683" txt_i="11283" txt_f="11405">Occurrence of contrast nephropathy (several definitions) according to the group of inclusion (placebo or n-acetylcysteine)</offsets></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col></colgroup><thead valign="top"><tr><th rowspan="2" align="left"><bold><offsets xml_i="20921" xml_f="20926" txt_i="11406" txt_f="11411">Event</offsets></bold></th><th align="left" valign="bottom"><bold><offsets xml_i="20977" xml_f="20984" txt_i="11411" txt_f="11418">Placebo</offsets></bold><hr></hr></th><th align="left" valign="bottom"><bold><offsets xml_i="21044" xml_f="21047" txt_i="11418" txt_f="11421">NAC</offsets></bold><hr></hr></th><th rowspan="2" align="left"><bold><offsets xml_i="21103" xml_f="21110" txt_i="11421" txt_f="11428">P-value</offsets></bold></th></tr><tr><th align="left"><bold><offsets xml_i="21154" xml_f="21156" txt_i="11428" txt_f="11430">(n</offsets></bold><offsets xml_i="21163" xml_f="21166" txt_i="11430" txt_f="11433"> = </offsets><bold><offsets xml_i="21172" xml_f="21175" txt_i="11433" txt_f="11436">58)</offsets></bold></th><th align="left"><bold><offsets xml_i="21210" xml_f="21212" txt_i="11436" txt_f="11438">(n</offsets></bold><offsets xml_i="21219" xml_f="21222" txt_i="11438" txt_f="11441"> = </offsets><bold><offsets xml_i="21228" xml_f="21231" txt_i="11441" txt_f="11444">52)</offsets></bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><offsets xml_i="21313" xml_f="21353" txt_i="11444" txt_f="11484">25% increase of creatinine or cystatin C</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="21400" xml_f="21410" txt_i="11485" txt_f="11495">13 (22.4%)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="21457" xml_f="21467" txt_i="11496" txt_f="11506">14 (26.9%)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="21514" xml_f="21518" txt_i="11507" txt_f="11511">0.66</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="21574" xml_f="21597" txt_i="11512" txt_f="11535">25% increase creatinine</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="21644" xml_f="21654" txt_i="11536" txt_f="11546">10 (17.2%)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="21701" xml_f="21710" txt_i="11547" txt_f="11556">8 (15.4%)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="21757" xml_f="21761" txt_i="11557" txt_f="11561">0.99</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="21817" xml_f="21840" txt_i="11562" txt_f="11585">25% increase cystatin C</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="21887" xml_f="21896" txt_i="11586" txt_f="11595">9 (15.5%)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="21943" xml_f="21952" txt_i="11596" txt_f="11605">9 (17.3%)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="21999" xml_f="22003" txt_i="11606" txt_f="11610">0.99</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="22059" xml_f="22071" txt_i="11611" txt_f="11623">AKIN stage 1</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="22118" xml_f="22128" txt_i="11624" txt_f="11634">11 (19.0%)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="22175" xml_f="22185" txt_i="11635" txt_f="11645">13 (25.0%)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="22232" xml_f="22236" txt_i="11646" txt_f="11650">0.49</offsets><hr></hr></td></tr><tr><td align="left"><offsets xml_i="22276" xml_f="22291" txt_i="11651" txt_f="11666">AKIN all stages</offsets></td><td align="left"><offsets xml_i="22313" xml_f="22323" txt_i="11667" txt_f="11677">12 (20.7%)</offsets></td><td align="left"><offsets xml_i="22345" xml_f="22355" txt_i="11678" txt_f="11688">13 (25.0%)</offsets></td><td align="left"><offsets xml_i="22377" xml_f="22381" txt_i="11689" txt_f="11693">0.65</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="22423" xml_f="22540" txt_i="11694" txt_f="11811">The variations in creatinine and cystatin C concentrations on days 2, 4 and 10 in both groups are reported in Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="22570" xml_f="22571" txt_i="11811" txt_f="11812">2</offsets></xref><offsets xml_i="22578" xml_f="22886" txt_i="11812" txt_f="12120">. The evolution from baseline to day 10 in creatinine and cystatin C levels concentration was not different between the two groups. At Day 10, both cystatin C and creatinine were lower than baseline suggesting that acute renal insufficiency was participating in the renal impairment observed at day 0 (Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="22918" xml_f="22919" txt_i="12120" txt_f="12121">3</offsets></xref><offsets xml_i="22926" xml_f="22928" txt_i="12121" txt_f="12123">).</offsets></p><fig id="F2" position="float"><label><offsets xml_i="22969" xml_f="22977" txt_i="12124" txt_f="12132">Figure 2</offsets></label><caption><p><bold><offsets xml_i="23003" xml_f="23080" txt_i="12132" txt_f="12209">Median and dispersion of the evolution of creatinine and cystatin C after CT.</offsets></bold><offsets xml_i="23087" xml_f="23089" txt_i="12209" txt_f="12211"> (</offsets><bold><offsets xml_i="23095" xml_f="23096" txt_i="12211" txt_f="12212">a</offsets></bold><offsets xml_i="23103" xml_f="23273" txt_i="12212" txt_f="12382">) Median and dispersion of the evolution of creatinine at day 0, day 2, day 4 and day 10 after CT in the N-acetylcysteine group (white) and in the control group (grey); (</offsets><bold><offsets xml_i="23279" xml_f="23280" txt_i="12382" txt_f="12383">b</offsets></bold><offsets xml_i="23287" xml_f="23455" txt_i="12383" txt_f="12551">) Median and dispersion of the evolution of cystatin C at day 0, day 2, day 4 and day 10 after CT in the N-acetylcysteine group (white) and in the control group (grey).</offsets></p></caption><graphic xlink:href="1471-2369-14-119-2"></graphic></fig><table-wrap position="float" id="T3"><label><offsets xml_i="23570" xml_f="23577" txt_i="12552" txt_f="12559">Table 3</offsets></label><caption><p><offsets xml_i="23597" xml_f="23699" txt_i="12559" txt_f="12661">Mean increases in creatinine and cystatin C on days 2, 4 and 10 compared with day 0, in the two groups</offsets></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col></colgroup><thead valign="top"><tr><th rowspan="2" align="left"><offsets xml_i="23931" xml_f="23932" txt_i="12662" txt_f="12663"> </offsets></th><th align="left" valign="bottom"><bold><offsets xml_i="23976" xml_f="23983" txt_i="12663" txt_f="12670">Placebo</offsets></bold><hr></hr></th><th align="left" valign="bottom"><bold><offsets xml_i="24043" xml_f="24046" txt_i="12670" txt_f="12673">NAC</offsets></bold><hr></hr></th><th rowspan="2" align="left"><bold><offsets xml_i="24102" xml_f="24109" txt_i="12673" txt_f="12680">P-value</offsets></bold></th></tr><tr><th align="left"><bold><offsets xml_i="24153" xml_f="24155" txt_i="12680" txt_f="12682">(n</offsets></bold><offsets xml_i="24162" xml_f="24165" txt_i="12682" txt_f="12685"> = </offsets><bold><offsets xml_i="24171" xml_f="24174" txt_i="12685" txt_f="12688">58)</offsets></bold></th><th align="left"><bold><offsets xml_i="24209" xml_f="24211" txt_i="12688" txt_f="12690">(n</offsets></bold><offsets xml_i="24218" xml_f="24221" txt_i="12690" txt_f="12693"> = </offsets><bold><offsets xml_i="24227" xml_f="24230" txt_i="12693" txt_f="12696">52)</offsets></bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold><offsets xml_i="24318" xml_f="24323" txt_i="12696" txt_f="12701">Day 2</offsets></bold><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="24377" xml_f="24378" txt_i="12702" txt_f="12703"> </offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="24425" xml_f="24426" txt_i="12704" txt_f="12705"> </offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="24473" xml_f="24474" txt_i="12706" txt_f="12707"> </offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="24530" xml_f="24542" txt_i="12708" txt_f="12720">  Creatinine</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="24589" xml_f="24602" txt_i="12721" txt_f="12734">−3.60 ± 35.84</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="24649" xml_f="24662" txt_i="12735" txt_f="12748">−3.66 ± 38.69</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="24709" xml_f="24713" txt_i="12749" txt_f="12753">0.96</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="24769" xml_f="24781" txt_i="12754" txt_f="12766">  Cystatin C</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="24828" xml_f="24839" txt_i="12767" txt_f="12778">−0.02 ±0.43</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="24886" xml_f="24897" txt_i="12779" txt_f="12790">0.06 ± 0.44</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="24944" xml_f="24948" txt_i="12791" txt_f="12795">0.30</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><bold><offsets xml_i="25010" xml_f="25015" txt_i="12796" txt_f="12801">Day 4</offsets></bold><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="25069" xml_f="25070" txt_i="12802" txt_f="12803"> </offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="25117" xml_f="25118" txt_i="12804" txt_f="12805"> </offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="25165" xml_f="25166" txt_i="12806" txt_f="12807"> </offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="25222" xml_f="25234" txt_i="12808" txt_f="12820">  Creatinine</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="25281" xml_f="25294" txt_i="12821" txt_f="12834">−8.25 ± 65.62</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="25341" xml_f="25354" txt_i="12835" txt_f="12848">−8.37 ± 36.52</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="25401" xml_f="25405" txt_i="12849" txt_f="12853">0.37</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="25461" xml_f="25473" txt_i="12854" txt_f="12866">  Cystatin C</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="25520" xml_f="25532" txt_i="12867" txt_f="12879">−0.04 ± 0.57</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="25579" xml_f="25591" txt_i="12880" txt_f="12892">−0.04 ± 0.41</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="25638" xml_f="25642" txt_i="12893" txt_f="12897">0.30</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><bold><offsets xml_i="25704" xml_f="25710" txt_i="12898" txt_f="12904">Day 10</offsets></bold><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="25764" xml_f="25765" txt_i="12905" txt_f="12906"> </offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="25812" xml_f="25813" txt_i="12907" txt_f="12908"> </offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="25860" xml_f="25861" txt_i="12909" txt_f="12910"> </offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="25917" xml_f="25929" txt_i="12911" txt_f="12923">  Creatinine</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="25976" xml_f="25990" txt_i="12924" txt_f="12938">−14.94 ± 75.53</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="26037" xml_f="26051" txt_i="12939" txt_f="12953">−16.53 ± 25.23</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="26098" xml_f="26102" txt_i="12954" txt_f="12958">0.25</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="26158" xml_f="26170" txt_i="12959" txt_f="12971">  Cystatin C</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="26217" xml_f="26229" txt_i="12972" txt_f="12984">−0.12 ± 0.54</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="26276" xml_f="26288" txt_i="12985" txt_f="12997">−0.07 ± 0.34</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="26335" xml_f="26339" txt_i="12998" txt_f="13002">0.27</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><bold><offsets xml_i="26401" xml_f="26414" txt_i="13003" txt_f="13016">Peak increase</offsets></bold><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="26468" xml_f="26469" txt_i="13017" txt_f="13018"> </offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="26516" xml_f="26517" txt_i="13019" txt_f="13020"> </offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="26564" xml_f="26565" txt_i="13021" txt_f="13022"> </offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="26621" xml_f="26633" txt_i="13023" txt_f="13035">  Creatinine</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="26680" xml_f="26692" txt_i="13036" txt_f="13048">9.38 ± 70.91</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="26739" xml_f="26751" txt_i="13049" txt_f="13061">4.63 ± 38.14</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="26798" xml_f="26802" txt_i="13062" txt_f="13066">0.54</offsets><hr></hr></td></tr><tr><td align="left"><offsets xml_i="26842" xml_f="26854" txt_i="13067" txt_f="13079">  Cystatin C</offsets></td><td align="left"><offsets xml_i="26876" xml_f="26887" txt_i="13080" txt_f="13091">0.06 ± 0.56</offsets></td><td align="left"><offsets xml_i="26909" xml_f="26920" txt_i="13092" txt_f="13103">0.17 ± 0.43</offsets></td><td align="left"><offsets xml_i="26942" xml_f="26946" txt_i="13104" txt_f="13108">0.07</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="26988" xml_f="27434" txt_i="13109" txt_f="13555">None of the sensitivity analyses, performed to explore the impact of loss to follow-up or death, led to a quantitatively different result: all p-value ranged between 0.30 and 0.99. In particular, the composite event of death or acute kidney injury occurred in 14 (24%) of 58 patients (after exclusion of the patient lost to follow-up) in the placebo group, and in 18 (33%) of 54 patients in NAC group (including the 2 patients who died at day 0).</offsets></p><p><offsets xml_i="27441" xml_f="27671" txt_i="13556" txt_f="13786">A correlation coefficient was computed between creatinine levels and cystatin C levels at day 2, 4 and 10. The correlation was of 0.87 at day 2, 0.83 at day 4 and 0.67 at day 10 demonstrating a good congruence of the two measures.</offsets></p><p><offsets xml_i="27678" xml_f="27757" txt_i="13787" txt_f="13866">No side effects attributed to NAC injection were observed throughout the study.</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="27807" xml_f="27817" txt_i="13869" txt_f="13879">Discussion</offsets></title><p><offsets xml_i="27828" xml_f="28148" txt_i="13880" txt_f="14200">This study demonstrates that ultra-high dose intravenous NAC does not prevent contrast-induced nephropathy in patients with impaired renal function undergoing emergency contrast CT-Scan, whatever the definition used for the condition and independently of the use of creatinine or cystatin C as markers of renal function.</offsets></p><p><offsets xml_i="28155" xml_f="28477" txt_i="14201" txt_f="14523">In this work, we used both the classical definition of contrast nephropathy (25% increase in serum creatinine or absolute increase of 44 umo/l of creatinine), as well as cystatin C and AKIN criteria. AKIN critera have been recently demonstrated to be predictive of hospital mortality contrast nephropathy in ICU patients [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="28508" xml_f="28509" txt_i="14523" txt_f="14524">7</offsets></xref><offsets xml_i="28516" xml_f="28875" txt_i="14524" txt_f="14883">]. The use of different definition did not modify the fact that iv NAC did not protect against contrast nephropathy, but altered the prevalence of events in our population as it could range from 16 to 24.5% depending on the definition used. More studies are needed to determine which definition best predicts mortality in ER patients after contrast injection.</offsets></p><p><offsets xml_i="28882" xml_f="29717" txt_i="14884" txt_f="15719">This study focuses on a poorly studied and fragile population, namely patients from the ER with elevated creatinine levels undergoing emergency CT-Scan. This population is important since it is a large population in which standard preparation before contrast injection is impossible due to time constraints. In addition these patients usually require rapid and often multiple radiologic examinations. Furthermore, appreciation of the basal renal function of these patients is difficult given a usually unique measurement of creatinine level available. In this study, we observe that approximately one out of four patients presenting to the ER with an elevated creatinine undergoing contrast CT-Scan level will develop contrast nephropathy. This high incidence differs from the incidence described post angiography or post elective CT [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="29749" xml_f="29751" txt_i="15719" txt_f="15721">23</offsets></xref><offsets xml_i="29758" xml_f="30850" txt_i="15721" txt_f="16813">], demonstrating that emergency CT in a high risk population is still an important cause of AKI. It is however probable that a significant percentage of these observed AKI are multifactorial. Indeed, according to the severity of the medical conditions and the emergency setting, associated ischemic AKI might contribute to this high incidence. The study was not designed for this purpose but each patient was treated according to the medical illness necessitating the emergency CT SCAN, which includes treatments to prevent or minimize AKI. This is illustrated by the decrease in mean creatinine at Day 10 as compared to baseline creatinine. Nevertheless, we do not think that it does change the conclusion of the study regarding the role of NAC in this setting as our results demonstrate than NAC administration does not alter this renal evolution. The search for efficient and rapid means of prevention of contrast nephropathy in patients with decreased renal function undergoing emergency CT is therefore of paramount importance and should take into account the risk of multifactorial AKI.</offsets></p><p><offsets xml_i="30857" xml_f="31036" txt_i="16814" txt_f="16993">NAC possesses potential anti-oxidant and hemodynamic properties that have been hypothesized to protect against contrast nephropathy. Since 2000 and the princeps study from Tepel [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="31068" xml_f="31070" txt_i="16993" txt_f="16995">13</offsets></xref><offsets xml_i="31077" xml_f="31427" txt_i="16995" txt_f="17345">], it has been used extensively for renal protection together with hydration before contrast medium use. However, data in the literature are variable and even meta-analysis are conflicting due to variation of protocols used, heterogeneicity of studies and to publication bias toward positive studies in either oral or intravenous NAC administration [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="31459" xml_f="31461" txt_i="17345" txt_f="17347">15</offsets></xref><offsets xml_i="31468" xml_f="31469" txt_i="17347" txt_f="17348">,</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="31501" xml_f="31503" txt_i="17348" txt_f="17350">24</offsets></xref><offsets xml_i="31510" xml_f="31511" txt_i="17350" txt_f="17351">-</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="31543" xml_f="31545" txt_i="17351" txt_f="17353">27</offsets></xref><offsets xml_i="31552" xml_f="31687" txt_i="17353" txt_f="17488">]. Moreover the largest trial on oral NAC to date observed no effect of this drug in preventing contrast nephropathy post angiography [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="31719" xml_f="31721" txt_i="17488" txt_f="17490">28</offsets></xref><offsets xml_i="31728" xml_f="31862" txt_i="17490" txt_f="17624">]. However Marenzi and collegues describe a dose dependent protection of NAC, potentially contributing to the variability of results [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="31894" xml_f="31896" txt_i="17624" txt_f="17626">17</offsets></xref><xref ref-type="bibr" rid="B29"><offsets xml_i="31935" xml_f="31937" txt_i="17626" txt_f="17628">29</offsets></xref><offsets xml_i="31944" xml_f="32154" txt_i="17628" txt_f="17838">]. However, in an emergency setting, when large quantity of fluids have to be administrated in a short period of time, in patients with uncertain cardiac function, we consider that the use of a 0.45% solution [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="32186" xml_f="32188" txt_i="17838" txt_f="17840">30</offsets></xref><offsets xml_i="32195" xml_f="32249" txt_i="17840" txt_f="17894">] is more appropriated to avoid acute pulmonary edema.</offsets></p><p><offsets xml_i="32256" xml_f="32373" txt_i="17895" txt_f="18012">A role of NAC on creatinine secretion independently of kidney filtration has been reported by Hoffman and collegues [</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="32405" xml_f="32407" txt_i="18012" txt_f="18014">31</offsets></xref><offsets xml_i="32414" xml_f="32740" txt_i="18014" txt_f="18340">]. To correct for this, we also measured cystatin C at all time points of our study. We observed no effect of NAC on AKI based on creatinine or cystatin C level. Furthermore, cystatin C and creatinine levels showed a good correlation at all time points, arguing against a major role of intravenous NAC on creatinine secretion.</offsets></p><p><offsets xml_i="32747" xml_f="33837" txt_i="18341" txt_f="19431">Our study is limited by some aspects. First our population is relatively small and we cannot exclude a minor effect of NAC that might have been detectable in a larger cohort. However, such a small effect would probably not be relevant in clinical practice. Second our selection criteria were based on a single creatinine level measurement in the ER. We may therefore have mixed acute and chronic cases of renal impairment, rendering our population less homogenous than in previous studies but closer to everyday practice in the ER. The high rate of CN demonstrates that this population was in any cases vulnerable. Finally, the contrast medium dose used for CT-Scan is generally lower than for cardiac angiography which has been the situation mostly studied regarding NAC effect. Despite these limitations, the follow up of patients with two renal markers, the very high dose of NAC and different definitions of AKI used are strong arguments against an effect of IV NAC on AKI prevention in patients presenting on the ER with a decreased estimated clearance and undergoing contrast CT-Scan.</offsets></p></sec><sec sec-type="conclusions"><title><offsets xml_i="33882" xml_f="33893" txt_i="19433" txt_f="19444">Conclusions</offsets></title><p><offsets xml_i="33904" xml_f="34202" txt_i="19445" txt_f="19743">In summary, contrast-induced nephropathy incidence is high in patients with a low estimated GFR undergoing an emergency CT-Scan. Intravenous NAC at high dose is not more efficient in this population than hydration alone for prevention of contrast nephropathy and should not be used in this setting.</offsets></p></sec><sec><title><offsets xml_i="34224" xml_f="34243" txt_i="19745" txt_f="19764">Competing interests</offsets></title><p><offsets xml_i="34254" xml_f="34368" txt_i="19765" txt_f="19879">The authors have no commercial, financial or any other interest to disclose with regard to the current submission.</offsets></p></sec><sec><title><offsets xml_i="34390" xml_f="34412" txt_i="19881" txt_f="19903">Authors’ contributions</offsets></title><p><offsets xml_i="34423" xml_f="34949" txt_i="19904" txt_f="20430">PAP, AP, and PYM did conceive the study. PAP, AP, SDS, FS, CDB, PS and PYM did equally contribute to the design of the study. PAP and AP did collect the data and obtained the informed consent. EDL and TP performed the statistical analysis of the data. PAP, AP, EDL, TP and PS carried the data analysis and interpretation. PAP, AP, SDS, FS, CDB and PYM did participate to the drafting of the manuscript. PAP, CDB and PYM did participate to the coordination of the whole study. All authors read and approve the final manuscript.</offsets></p></sec><sec><title><offsets xml_i="34971" xml_f="34991" txt_i="20432" txt_f="20452">Authors’ information</offsets></title><p><offsets xml_i="35002" xml_f="35638" txt_i="20453" txt_f="21089">PAP and AP are specialized in emergency radiology. They are members of a research team in this field. They are particularly concerned by the optimization of the protocols in the emergency department, to improve the quality of care and efficiency in managing emergency patients. SDS, PYM and PS are specialized in clinical nephrology. They are in charge of the treatment and the prevention of acute renal failure in patients admitted in our hospital. Thus, they are particularly concern by contrast nephrotoxicity in vulnerable patients. CDB is head of the radiology department. EDL and TP are specialists in epidemiology and statistics.</offsets></p></sec><sec><title><offsets xml_i="35660" xml_f="35683" txt_i="21091" txt_f="21114">Pre-publication history</offsets></title><p><offsets xml_i="35694" xml_f="35758" txt_i="21115" txt_f="21179">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2369/14/119/prepub"><offsets xml_i="35861" xml_f="35913" txt_i="21180" txt_f="21232">http://www.biomedcentral.com/1471-2369/14/119/prepub</offsets></ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>We thank Udo Hasler for his contribution in the editing of the manuscript.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Levy</surname><given-names>EM</given-names></name><name><surname>Viscoli</surname><given-names>CM</given-names></name><name><surname>Horwitz</surname><given-names>RI</given-names></name><article-title>The effect of acute renal failure on mortality. A cohort analysis</article-title><source>JAMA</source><year>1996</year><volume>275</volume><issue>19</issue><fpage>1489</fpage><lpage>1494</lpage><pub-id pub-id-type="pmid">8622223</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Thomsen</surname><given-names>HS</given-names></name><article-title>Guidelines for contrast media from the european society of urogenital radiology</article-title><source>AJR Am J Roentgenol</source><year>2003</year><volume>181</volume><issue>6</issue><fpage>1463</fpage><lpage>1471</lpage><pub-id pub-id-type="pmid">14627556</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Mehta</surname><given-names>RL</given-names></name><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Shah</surname><given-names>SV</given-names></name><name><surname>Molitoris</surname><given-names>BA</given-names></name><name><surname>Ronco</surname><given-names>C</given-names></name><name><surname>Warnock</surname><given-names>DG</given-names></name><name><surname>Levin</surname><given-names>A</given-names></name><article-title>Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury</article-title><source>Crit Care</source><year>2007</year><volume>11</volume><issue>2</issue><fpage>R31</fpage><pub-id pub-id-type="pmid">17331245</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Barrantes</surname><given-names>F</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Ivanov</surname><given-names>O</given-names></name><name><surname>Yalamanchili</surname><given-names>HB</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Buenafe</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>V</given-names></name><name><surname>Dijeh</surname><given-names>S</given-names></name><name><surname>Amoateng-Adjepong</surname><given-names>Y</given-names></name><name><surname>Manthous</surname><given-names>CA</given-names></name><article-title>Acute kidney injury predicts outcomes of non-critically ill patients</article-title><source>Mayo Clin Proc</source><year>2009</year><volume>84</volume><issue>5</issue><fpage>410</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">19411437</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Barrantes</surname><given-names>F</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Vazquez</surname><given-names>R</given-names></name><name><surname>Amoateng-Adjepong</surname><given-names>Y</given-names></name><name><surname>Manthous</surname><given-names>CA</given-names></name><article-title>Acute kidney injury criteria predict outcomes of critically ill patients</article-title><source>Crit Care Med</source><year>2008</year><volume>36</volume><issue>5</issue><fpage>1397</fpage><lpage>1403</lpage><pub-id pub-id-type="pmid">18434915</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Barrantes</surname><given-names>F</given-names></name><name><surname>Amoateng-Adjepong</surname><given-names>Y</given-names></name><name><surname>Manthous</surname><given-names>CA</given-names></name><article-title>Rapid reversal of acute kidney injury and hospital outcomes: a retrospective cohort study</article-title><source>Am J Kidney Dis</source><year>2009</year><volume>53</volume><issue>6</issue><fpage>974</fpage><lpage>981</lpage><pub-id pub-id-type="pmid">19362401</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Lakhal</surname><given-names>K</given-names></name><name><surname>Ehrmann</surname><given-names>S</given-names></name><name><surname>Chaari</surname><given-names>A</given-names></name><name><surname>Laissy</surname><given-names>JP</given-names></name><name><surname>Regnier</surname><given-names>B</given-names></name><name><surname>Wolff</surname><given-names>M</given-names></name><name><surname>Pajot</surname><given-names>O</given-names></name><article-title>Acute kidney injury network definition of contrast-induced nephropathy in the critically ill: incidence and outcome</article-title><source>J Crit Care</source><year>2011</year><volume>26</volume><issue>6</issue><fpage>593</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">21737245</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Kwon</surname><given-names>SH</given-names></name><name><surname>Hyun</surname><given-names>J</given-names></name><name><surname>Jeon</surname><given-names>JS</given-names></name><name><surname>Noh</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>DC</given-names></name><article-title>Subtle change of cystatin C, with or without acute kidney injury, associated with increased mortality in the intensive care unit</article-title><source>J Crit Care</source><year>2011</year><volume>27</volume><issue>3</issue><fpage>293</fpage><lpage>300</lpage></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Bartholomew</surname><given-names>BA</given-names></name><name><surname>Harjai</surname><given-names>KJ</given-names></name><name><surname>Dukkipati</surname><given-names>S</given-names></name><name><surname>Boura</surname><given-names>JA</given-names></name><name><surname>Yerkey</surname><given-names>MW</given-names></name><name><surname>Glazier</surname><given-names>S</given-names></name><name><surname>Grines</surname><given-names>CL</given-names></name><name><surname>O’Neill</surname><given-names>WW</given-names></name><article-title>Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification</article-title><source>Am J Cardiol</source><year>2004</year><volume>93</volume><issue>12</issue><fpage>1515</fpage><lpage>1519</lpage><pub-id pub-id-type="pmid">15194023</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Lencioni</surname><given-names>R</given-names></name><name><surname>Fattori</surname><given-names>R</given-names></name><name><surname>Morana</surname><given-names>G</given-names></name><name><surname>Stacul</surname><given-names>F</given-names></name><article-title>Contrast-induced nephropathy in patients undergoing computed tomography (CONNECT) - a clinical problem in daily practice? A multicenter observational study</article-title><source>Acta Radiol</source><year>2010</year><volume>51</volume><issue>7</issue><fpage>741</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">20707658</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Parfrey</surname><given-names>P</given-names></name><article-title>The clinical epidemiology of contrast-induced nephropathy</article-title><source>Cardiovasc Intervent Radiol</source><year>2005</year><volume>28</volume><issue>Suppl 2</issue><fpage>S3</fpage><lpage>S11</lpage><pub-id pub-id-type="pmid">16419277</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Parfrey</surname><given-names>PS</given-names></name><name><surname>Griffiths</surname><given-names>SM</given-names></name><name><surname>Barrett</surname><given-names>BJ</given-names></name><name><surname>Paul</surname><given-names>MD</given-names></name><name><surname>Genge</surname><given-names>M</given-names></name><name><surname>Withers</surname><given-names>J</given-names></name><name><surname>Farid</surname><given-names>N</given-names></name><name><surname>McManamon</surname><given-names>PJ</given-names></name><article-title>Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study</article-title><source>N Engl J Med</source><year>1989</year><volume>320</volume><issue>3</issue><fpage>143</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">2643041</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Tepel</surname><given-names>M</given-names></name><name><surname>van der Giet</surname><given-names>M</given-names></name><name><surname>Schwarzfeld</surname><given-names>C</given-names></name><name><surname>Laufer</surname><given-names>U</given-names></name><name><surname>Liermann</surname><given-names>D</given-names></name><name><surname>Zidek</surname><given-names>W</given-names></name><article-title>Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><issue>3</issue><fpage>180</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">10900277</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Eisenberg</surname><given-names>RL</given-names></name><name><surname>Bank</surname><given-names>WO</given-names></name><name><surname>Hedgock</surname><given-names>MW</given-names></name><article-title>Renal failure after major angiography can be avoided with hydration</article-title><source>AJR Am J Roentgenol</source><year>1981</year><volume>136</volume><issue>5</issue><fpage>859</fpage><lpage>861</lpage><pub-id pub-id-type="pmid">6784516</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Stacul</surname><given-names>F</given-names></name><name><surname>Adam</surname><given-names>A</given-names></name><name><surname>Becker</surname><given-names>CR</given-names></name><name><surname>Davidson</surname><given-names>C</given-names></name><name><surname>Lameire</surname><given-names>N</given-names></name><name><surname>McCullough</surname><given-names>PA</given-names></name><name><surname>Tumlin</surname><given-names>J</given-names></name><article-title>Strategies to reduce the risk of contrast-induced nephropathy</article-title><source>Am J Cardiol</source><year>2006</year><volume>98</volume><issue>6A</issue><fpage>59K</fpage><lpage>77K</lpage></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Carbonell</surname><given-names>N</given-names></name><name><surname>Blasco</surname><given-names>M</given-names></name><name><surname>Sanjuan</surname><given-names>R</given-names></name><name><surname>Perez-Sancho</surname><given-names>E</given-names></name><name><surname>Sanchis</surname><given-names>J</given-names></name><name><surname>Insa</surname><given-names>L</given-names></name><name><surname>Bodi</surname><given-names>V</given-names></name><name><surname>Nunez</surname><given-names>J</given-names></name><name><surname>Garcia-Ramon</surname><given-names>R</given-names></name><name><surname>Miguel</surname><given-names>A</given-names></name><article-title>Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial</article-title><source>Int J Cardiol</source><year>2007</year><volume>115</volume><issue>1</issue><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">16814414</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Marenzi</surname><given-names>G</given-names></name><name><surname>Assanelli</surname><given-names>E</given-names></name><name><surname>Marana</surname><given-names>I</given-names></name><name><surname>Lauri</surname><given-names>G</given-names></name><name><surname>Campodonico</surname><given-names>J</given-names></name><name><surname>Grazi</surname><given-names>M</given-names></name><name><surname>De Metrio</surname><given-names>M</given-names></name><name><surname>Galli</surname><given-names>S</given-names></name><name><surname>Fabbiocchi</surname><given-names>F</given-names></name><name><surname>Montorsi</surname><given-names>P</given-names></name><etal></etal><article-title>N-acetylcysteine and contrast-induced nephropathy in primary angioplasty</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><issue>26</issue><fpage>2773</fpage><lpage>2782</lpage><pub-id pub-id-type="pmid">16807414</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Baker</surname><given-names>CS</given-names></name><name><surname>Wragg</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>De Palma</surname><given-names>R</given-names></name><name><surname>Baker</surname><given-names>LR</given-names></name><name><surname>Knight</surname><given-names>CJ</given-names></name><article-title>A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study</article-title><source>J Am Coll Cardiol</source><year>2003</year><volume>41</volume><issue>12</issue><fpage>2114</fpage><lpage>2118</lpage><pub-id pub-id-type="pmid">12821233</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Shalansky</surname><given-names>SJ</given-names></name><name><surname>Pate</surname><given-names>GE</given-names></name><name><surname>Levin</surname><given-names>A</given-names></name><name><surname>Webb</surname><given-names>JG</given-names></name><article-title>N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration</article-title><source>Heart</source><year>2005</year><volume>91</volume><issue>8</issue><fpage>997</fpage><lpage>999</lpage><pub-id pub-id-type="pmid">16020580</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Poletti</surname><given-names>PA</given-names></name><name><surname>Saudan</surname><given-names>P</given-names></name><name><surname>Platon</surname><given-names>A</given-names></name><name><surname>Mermillod</surname><given-names>B</given-names></name><name><surname>Sautter</surname><given-names>AM</given-names></name><name><surname>Vermeulen</surname><given-names>B</given-names></name><name><surname>Sarasin</surname><given-names>FP</given-names></name><name><surname>Becker</surname><given-names>CD</given-names></name><name><surname>Martin</surname><given-names>PY</given-names></name><article-title>I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity</article-title><source>AJR Am J Roentgenol</source><year>2007</year><volume>189</volume><issue>3</issue><fpage>687</fpage><lpage>692</lpage><pub-id pub-id-type="pmid">17715118</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Bosch</surname><given-names>JP</given-names></name><name><surname>Lewis</surname><given-names>JB</given-names></name><name><surname>Greene</surname><given-names>T</given-names></name><name><surname>Rogers</surname><given-names>N</given-names></name><name><surname>Roth</surname><given-names>D</given-names></name><article-title>A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group</article-title><source>Ann Intern Med</source><year>1999</year><volume>130</volume><issue>6</issue><fpage>461</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">10075613</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Molitoris</surname><given-names>BA</given-names></name><name><surname>Levin</surname><given-names>A</given-names></name><name><surname>Warnock</surname><given-names>DG</given-names></name><name><surname>Joannidis</surname><given-names>M</given-names></name><name><surname>Mehta</surname><given-names>RL</given-names></name><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Ronco</surname><given-names>C</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><article-title>Improving outcomes from acute kidney injury</article-title><source>J Am Soc Nephrol</source><year>2007</year><volume>18</volume><issue>7</issue><fpage>1992</fpage><lpage>1994</lpage><pub-id pub-id-type="pmid">17596636</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Weisbord</surname><given-names>SD</given-names></name><name><surname>Mor</surname><given-names>MK</given-names></name><name><surname>Resnick</surname><given-names>AL</given-names></name><name><surname>Hartwig</surname><given-names>KC</given-names></name><name><surname>Palevsky</surname><given-names>PM</given-names></name><name><surname>Fine</surname><given-names>MJ</given-names></name><article-title>Incidence and outcomes of contrast-induced AKI following computed tomography</article-title><source>Clin J Am Soc Nephrol</source><year>2008</year><volume>3</volume><issue>5</issue><fpage>1274</fpage><lpage>1281</lpage><pub-id pub-id-type="pmid">18463172</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Kelly</surname><given-names>AM</given-names></name><name><surname>Dwamena</surname><given-names>B</given-names></name><name><surname>Cronin</surname><given-names>P</given-names></name><name><surname>Bernstein</surname><given-names>SJ</given-names></name><name><surname>Carlos</surname><given-names>RC</given-names></name><article-title>Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy</article-title><source>Ann Intern Med</source><year>2008</year><volume>148</volume><issue>4</issue><fpage>284</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">18283206</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Caixeta</surname><given-names>A</given-names></name><name><surname>Mehran</surname><given-names>R</given-names></name><article-title>Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury</article-title><source>Catheter Cardiovasc Interv</source><year>2010</year><volume>75</volume><issue>Suppl 1</issue><fpage>S15</fpage><lpage>S20</lpage><pub-id pub-id-type="pmid">20333702</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Gonzales</surname><given-names>DA</given-names></name><name><surname>Norsworthy</surname><given-names>KJ</given-names></name><name><surname>Kern</surname><given-names>SJ</given-names></name><name><surname>Banks</surname><given-names>S</given-names></name><name><surname>Sieving</surname><given-names>PC</given-names></name><name><surname>Star</surname><given-names>RA</given-names></name><name><surname>Natanson</surname><given-names>C</given-names></name><name><surname>Danner</surname><given-names>RL</given-names></name><article-title>A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity</article-title><source>BMC Med</source><year>2007</year><volume>5</volume><fpage>32</fpage><pub-id pub-id-type="pmid">18001477</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Anderson</surname><given-names>SM</given-names></name><name><surname>Park</surname><given-names>ZH</given-names></name><name><surname>Patel</surname><given-names>RV</given-names></name><article-title>Intravenous N-acetylcysteine in the prevention of contrast media-induced nephropathy</article-title><source>Ann Pharmacother</source><year>2011</year><volume>45</volume><issue>1</issue><fpage>101</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">21205947</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><collab>ACT Investigators</collab><article-title>Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized acetylcysteine for contrast-induced nephropathy trial (ACT)</article-title><source>Circulation</source><year>2011</year><volume>124</volume><issue>11</issue><fpage>1250</fpage><lpage>1259</lpage><pub-id pub-id-type="pmid">21859972</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Bader</surname><given-names>BD</given-names></name><name><surname>Berger</surname><given-names>ED</given-names></name><name><surname>Heede</surname><given-names>MB</given-names></name><name><surname>Silberbaur</surname><given-names>I</given-names></name><name><surname>Duda</surname><given-names>S</given-names></name><name><surname>Risler</surname><given-names>T</given-names></name><name><surname>Erley</surname><given-names>CM</given-names></name><article-title>What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?</article-title><source>Clin Nephrol</source><year>2004</year><volume>62</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15267006</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Solomon</surname><given-names>R</given-names></name><name><surname>Werner</surname><given-names>C</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name><name><surname>D’Elia</surname><given-names>J</given-names></name><name><surname>Silva</surname><given-names>P</given-names></name><article-title>Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents</article-title><source>N Engl J Med</source><year>1994</year><volume>331</volume><issue>21</issue><fpage>1416</fpage><lpage>1420</lpage><pub-id pub-id-type="pmid">7969280</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Hoffmann</surname><given-names>U</given-names></name><name><surname>Fischereder</surname><given-names>M</given-names></name><name><surname>Kruger</surname><given-names>B</given-names></name><name><surname>Drobnik</surname><given-names>W</given-names></name><name><surname>Kramer</surname><given-names>BK</given-names></name><article-title>The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable</article-title><source>J Am Soc Nephrol</source><year>2004</year><volume>15</volume><issue>2</issue><fpage>407</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">14747387</pub-id></mixed-citation></ref></ref-list></back></article>